Predictive value of a new radiotherapy plan evaluation tool for bladder toxicity in cervical cancer
10.13491/j.issn.1004-714X.2024.02.014
- VernacularTitle:新型宫颈癌放疗计划评价工具对膀胱毒性的预测价值
- Author:
Qingxiao LIU
1
;
Yuexiang ZHU
1
;
Long TIAN
1
;
Songlin YANG
1
;
Zheng WANG
1
;
Yusen ZHAO
1
;
Zhiying REN
1
;
Maoye CHANG
1
Author Information
1. Medical Imaging Center, the First Affiliated Hospital of Hebei Northern University, Zhangjiakou 075000 China.
- Publication Type:OriginalArticles
- Keywords:
Cervical cancer;
Dose-surface histogram;
Dose-volume histogram;
Radiation cystitis;
Prediction
- From:
Chinese Journal of Radiological Health
2024;33(2):189-194
- CountryChina
- Language:Chinese
-
Abstract:
Objective To evaluate the predictive value of a dose-surface histogram (DSH) for radiation cystitis (RC) in patients with cervical cancer. Methods We retrospectively included 190 patients with cervical cancer who underwent image-guided radiotherapy (IGRT) from the HIS system of The First Affiliated Hospital of Hebei North University from May 2013 to May 2023. The patients were divided into test group (n = 100) and control group (n = 90). The dose distribution in the bladder was evaluated by using a DSH for the test group and using a dose-volume histogram (DVH) for the control group. Receiver operating characteristic curves were used to evaluate the predictive value of DSH for RC in comparison with DVH. Results There were no significant differences in baseline data and RC incidence between the two groups (all P＞0.05). All evaluation indicators were significantly different between DSH and DVH (all P＜0.05). The predictive value of S45 and V45 for the incidence of grade-I, -II, and -III RC was low (all P＜0.05). The predictive value of S50 and V50 for the incidence of grade-I, -II, and -III RC was moderate (all P＜0.05). S55−S57 and V55−V57 showed high value for predicting the incidence of grade-I, -II, and -III RC (all P＜0.05). Conclusion DSH shows basically the same predictive value for the incidence of RC caused by IGRT in cervical cancer as DVH, which is expected to become a new tool for evaluating radiotherapy plans.
